A new cancer drug candidate developed by Lawrence Livermore National Laboratory (LLNL), BBOT (BridgeBio Oncology Therapeutics) and the Frederick National Laboratory for Cancer Research (FNLCR) has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect. In early clinical trials, the compound, known as BBO-10203, has shown promise in disrupting a key interaction between two cancer-driving proteins — RAS and PI3Kα — without causing hyperglycemia (high blood-sugar levels), which has historically hindered similar treatments. Published in Science